Immunitas Therapeutics

Immunitas Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, in the United States. The company was founded to discover and develop novel, differentiated therapeutics for patients with cancer and autoimmune diseases, with a scientific focus on T cell biology and therapeutic antibodies. Its founding team brought together highly renowned cancer research and therapeutic antibody pioneers from several leading Boston-area research institutions, including Dana-Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. That founding team identified CD161 as a compelling T cell target for oncology, and their findings were published in Cell in 2021. Immunitas's lead program is IMT-009, an anti-CD161 antibody being developed for the treatment of solid tumors and hematological malignancies. The company has advanced IMT-009 into clinical development, presenting Phase 1/2a data highlighting anti-tumor activity at the AACR 2026 Annual Meeting, and has studied the agent both as a monotherapy and in combination with Fruquintinib in microsatellite stable colorectal cancer. A second program, IMT-380, is a first-in-class anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases; preclinical data on IMT-380 were presented at a FASEB Science Research Conference on Autoimmunity in 2025. This autoimmune program was recently licensed to Boehringer Ingelheim to advance treatments for chronic inflammatory diseases. The company positions itself around what it describes as novel biology and patient impact, pursuing differentiated antibody therapeutics rather than following established targets. Its pipeline spans oncology and autoimmune disease, both built on the CD161 target. Immunitas is a privately held company and operates primarily in the United States, with its corporate headquarters in Waltham, Massachusetts. It collaborates with larger pharmaceutical partners, as illustrated by the licensing agreement with Boehringer Ingelheim for its preclinical autoimmune antibody program.

Immunitas Therapeutics was founded to discover and develop novel, differentiated therapeutics for patients with cancer and autoimmune diseases. The company's scientific foundation was laid by a team of highly renowned cancer research and therapeutic antibody pioneers from Dana-Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. This founding team identified CD161 as a compelling T cell target for oncology, and their findings were published in Cell in 2021. The company is headquartered in Waltham, Massachusetts, in the United States. Building on this CD161 biology, Immunitas advanced its lead program, IMT-009, an anti-CD161 antibody for the treatment of solid tumors and hematological malignancies. The company has progressed IMT-009 into clinical development, including a first-in-human, dose-escalation and biomarker cohort expansion study in advanced cancer, and a Phase 1b combination with Fruquintinib in microsatellite stable colorectal cancer. In April 2026, Immunitas presented Phase 1/2a data highlighting the anti-tumor activity of IMT-009 at the AACR 2026 Annual Meeting, and in March 2026 announced it would present clinical data supporting the monotherapy and combination treatment potential of IMT-009 at the same meeting. Earlier, in April 2024, the company presented preclinical data supporting the combination of IMT-009 with anti-PD1 immunotherapy. Immunitas also developed a second program, IMT-380, a first-in-class anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases. In July 2025, the company presented preclinical data on IMT-380 at the FASEB Science Research Conference on Autoimmunity. In May 2026, Boehringer Ingelheim licensed this preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases, marking a significant partnership for the company's autoimmune pipeline. Across its history, Immunitas has positioned itself around novel biology and patient impact, pursuing differentiated antibody therapeutics built on the CD161 target across both oncology and autoimmune disease. The company remains a privately held, clinical-stage biotechnology company operating primarily in the United States.

• 2026

  Immunitas presented Phase 1/2a data highlighting the anti-tumor activity of IMT-009 at the AACR 2026 Annual Meeting.

• 2026

  Boehringer Ingelheim licensed Immunitas's preclinical antibody program to advance treatments for chronic inflammatory diseases.

• 2025

  Immunitas presented preclinical data on IMT-380, a first-in-class anti-CD161 antibody, at the FASEB Science Research Conference on Autoimmunity.

• 2024

  Immunitas presented preclinical data supporting the combination of IMT-009 with anti-PD1 immunotherapy.

• 2021

  Founding team's findings identifying CD161 as a compelling T cell target for oncology were published in Cell.

Clinical-stage biotechnology company developing novel, differentiated antibody therapeutics targeting CD161 for cancer and autoimmune diseases.

• IMT-009

  Lead program; an anti-CD161 antibody targeting CD161 for the treatment of solid tumors and hematological malignancies. Studied as monotherapy and in combination with Fruquintinib in microsatellite stable colorectal cancer.

• IMT-380

  A first-in-class anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases; licensed to Boehringer Ingelheim.

1. 1Immunitasimmunitastx.com
2. 2Immunitas Therapeutics (United States)wikidata.org